Compare FSP & SPRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FSP | SPRO |
|---|---|---|
| Founded | 1981 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 120.3M | 136.7M |
| IPO Year | N/A | 2017 |
| Metric | FSP | SPRO |
|---|---|---|
| Price | $0.97 | $2.30 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $5.00 |
| AVG Volume (30 Days) | ★ 854.0K | 473.5K |
| Earning Date | 10-28-2025 | 11-13-2025 |
| Dividend Yield | ★ 3.92% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $109,497,000.00 | $40,549,000.00 |
| Revenue This Year | $4.36 | N/A |
| Revenue Next Year | $0.81 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.87 | $0.51 |
| 52 Week High | $2.21 | $3.22 |
| Indicator | FSP | SPRO |
|---|---|---|
| Relative Strength Index (RSI) | 33.51 | 47.91 |
| Support Level | $1.39 | $2.18 |
| Resistance Level | $1.04 | $2.33 |
| Average True Range (ATR) | 0.06 | 0.11 |
| MACD | 0.02 | -0.02 |
| Stochastic Oscillator | 47.05 | 30.77 |
Franklin Street Properties Corp is a real estate investment trust. The company is focused on commercial real estate investments in office markets and currently operate in only one segment: real estate operations. The company's operations include rental income from real estate leasing, interest income from secured loans made on office properties, property dispositions, and fee income from asset/property management and development. Franklin Street markets Atlanta, Dallas, Denver, Houston, and Minneapolis.
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.